|
CENPC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.10218517540761E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.45480294477807E-11 |
| Normal-vs-Stage2 |
1.11588516205074E-12 |
| Normal-vs-Stage3 |
1.33226762955019E-15 |
| Normal-vs-Stage4 |
1.03128616757431E-12 |
| Stage1-vs-Stage2 |
7.292200E-02 |
| Stage1-vs-Stage3 |
1.405580E-01 |
| Stage1-vs-Stage4 |
9.523900E-02 |
| Stage2-vs-Stage3 |
5.178000E-01 |
| Stage2-vs-Stage4 |
7.063800E-01 |
| Stage3-vs-Stage4 |
7.820600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.14197540312944E-12 |
| Normal-vs-AfricanAmerican |
7.87030000000133E-05 |
| Normal-vs-Asian |
1.44599998641581E-09 |
| Caucasian-vs-AfricanAmerican |
1.365840E-01 |
| Caucasian-vs-Asian |
4.463400E-01 |
| AfricanAmerican-vs-Asian |
4.217200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.43915998510147E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.889800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.49880108324396E-11 |
| Normal-vs-Age(41-60Yrs) |
6.66133814775094E-16 |
| Normal-vs-Age(61-80Yrs) |
6.47260023356466E-14 |
| Normal-vs-Age(81-100Yrs) |
3.639200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.514200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.123700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.366000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.824200E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.344400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.536200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.340200E-03 |
| Classical-VS-Follicular |
7.023700E-02 |
| Classical-VS-Other |
5.283800E-01 |
| Classical-VS-Normal |
1.49329992815694E-10 |
| Tall-VS-Follicular |
2.920000E-01 |
| Tall-VS-Other |
4.674600E-01 |
| Tall-VS-Normal |
2.0264900868483E-12 |
| Follicular-VS-Other |
9.435200E-01 |
| Follicular-VS-Normal |
2.50999221407255E-12 |
| Other-VS-Normal |
1.378850E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.87316828714756E-12 |
| Normal-vs-N1 |
9.79989978056039E-10 |
| N0-vs-N1 |
4.943200E-01 |
|
|
